Preferred Label : Bortezomib;

MeSH definition : A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.;

MeSH hyponym : velcade; PS 341; LDP-341; LDP 341; LDP341; 341, PS; PS-341; PS341;

MeSH Related Number : 179324-69-7;

Wikipedia link : https://en.wikipedia.org/wiki/Bortezomib;

Is substance : O;

UNII : 69G8BD63PP;

Details


Main resources

You can consult :

A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.

https://ansm.sante.fr/tableau-acces-derogatoire/velcade-1-mg-poudre-pour-solution-injectable
2023
false
false
false
France
French
drug information
Bortezomib
injections, intravenous
Immunoglobulin Light-chain Amyloidosis
Non-amyloid monoclonal immunoglobulin deposition disease

---
https://www.has-sante.fr/jcms/p_3315479/fr/bortezomib-ever-pharma-bortezomib
2022
false
false
false
France
evaluation of the transparency committee
Bortezomib
bortezomib

---
https://www.has-sante.fr/jcms/p_3358121/fr/bortezomib-hospira-bortezomib-myelome-multiple-en-progression
2022
false
false
false
France
evaluation of the transparency committee
multiple myeloma
Myeloma
multiple myeloma
bortezomib
Myeloma
Bortezomib

---
https://www.has-sante.fr/jcms/p_3290537/fr/bortezomib-accord-2-5-mg/ml-bortezomib
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
Bortezomib
bortezomib
antineoplastic agents
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
lymphoma, mantle-cell
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3280987/fr/bortezomib-fresenius-kabi-2-5mg-bortezomib/-mannitol-ester-boronique-de
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
multiple myeloma
antineoplastic combined chemotherapy protocols
injections, subcutaneous
injections, intravenous
Multiple myeloma progression
antineoplastic agents
bortezomib
evaluation of the transparency committee
Bortezomib

---
https://www.has-sante.fr/jcms/p_3152655/fr/bortezomib-medac
2020
false
false
false
France
bortezomib
antineoplastic agents
proteasome inhibitors
multiple myeloma
treatment outcome
antineoplastic combined chemotherapy protocols
lymphoma, mantle-cell
adult
evaluation of the transparency committee
Bortezomib

---
https://www.has-sante.fr/jcms/p_3069193
2019
France
evaluation of the transparency committee
bortezomib
Bortezomib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-fresenius-kabi
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Bortezomib
Bortezomib
multiple myeloma
bortezomib
antineoplastic agents
antineoplastic agents
drugs, generic
adult
untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation
untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation
antineoplastic combined chemotherapy protocols
lymphoma, mantle-cell
injections, intravenous
injections, subcutaneous
proteasome inhibitors
proteasome inhibitors
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug compounding
Bortezomib/Liposomal Doxorubicin Regimen
VTD Regimen
VMP Regimen

---
https://www.has-sante.fr/jcms/p_3117093/fr/bortezomib-ohre-pharma
2019
false
false
false
France
bortezomib
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
multiple myeloma
antineoplastic agents
antineoplastic combined chemotherapy protocols
lymphoma, mantle-cell
adult
Bortezomib

---
https://www.has-sante.fr/jcms/c_2789189/fr/bortezomib-teva
2019
false
false
false
France
drugs, generic
evaluation of the transparency committee
bortezomib
Bortezomib

---
https://www.has-sante.fr/portail/jcms/c_2969198/fr/bortezomib-mylan
2019
false
false
false
France
drugs, generic
evaluation of the transparency committee
Bortezomib
bortezomib

---
https://www.has-sante.fr/portail/jcms/c_2962276/fr/bortezomib-teva
2019
false
true
false
false
France
Bortezomib
Powder for Injectable Solution Dosage Form
antineoplastic agents
multiple myeloma
Multiple myeloma progression
untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation
evaluation of the transparency committee

---
https://www.has-sante.fr/portail/jcms/c_2912413/fr/bortezomib-eg
2019
false
true
false
false
France
antineoplastic agents
multiple myeloma
adult
drug therapy, combination
lymphoma, mantle-cell
bortezomib
antineoplastic combined chemotherapy protocols
injections
evaluation of the transparency committee
bortezomib
Bortezomib

---
https://www.has-sante.fr/portail/jcms/c_2888477/fr/bortezomib-reddy-pharma
2018
false
false
false
France
evaluation of the transparency committee
bortezomib
Bortezomib

---
http://conseil-scientifique.public.lu/fr/publications/oncologie/bortezomib-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
multiple myeloma
guidelines for drug use
Bortezomib
bortezomib
proteasome inhibitors
injections, intravenous
antineoplastic agents
adult
disease progression
antineoplastic combined chemotherapy protocols

---
https://www.has-sante.fr/portail/jcms/c_2857808/fr/bortezomib-medac
2018
false
false
false
France
French
evaluation of the transparency committee
Bortezomib
bortezomib

---
https://www.ema.europa.eu/medicines/human/EPAR/Velcade
2016
false
United Kingdom
English
French
syndication feed
Bortezomib
Bortezomib
drug approval
europe
pregnancy
breast feeding
drug interactions
drug therapy, combination
adult
drug evaluation, preclinical
lymphoma, mantle-cell
injections, intravenous
antineoplastic agents
proteasome inhibitors
proteasome inhibitors
antineoplastic agents
multiple myeloma
treatment outcome
bortezomib
drug evaluation
summary of product characteristics
package leaflet

---
http://www.has-sante.fr/portail/jcms/c_2589998/fr/velcade
http://www.has-sante.fr/portail/jcms/c_2589998/fr/velcade-bortezomib-antineoplasique
2016
false
false
false
France
French
English
evaluation of the transparency committee
treatment outcome
bortezomib
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
injections, intravenous
adult
lymphoma, mantle-cell
survival analysis
Bortezomib
Bortezomib
guidelines for drug use
Progression-Free survival
disease-free survival

---
http://www.has-sante.fr/portail/jcms/c_2620016/fr/velcade
2016
false
true
false
France
French
evaluation of the transparency committee
treatment outcome
bortezomib
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
multiple myeloma
injections, intravenous
adult
induction chemotherapy
hematopoietic stem cell transplantation
Bortezomib
Bortezomib

---
http://www.has-sante.fr/portail/jcms/c_2620022/fr/velcade
2016
true
France
French
Bortezomib
proteasome inhibitors
multiple myeloma
disease progression
treatment outcome
evaluation of the transparency committee
Multiple myeloma progression
antineoplastic combined chemotherapy protocols
adult
recurrence
Myeloma recurrence
antineoplastic agents
bortezomib

---
https://www.ema.europa.eu/medicines/human/EPAR/Bortezomib-Sun
2016
false
United Kingdom
English
French
syndication feed
Bortezomib
Bortezomib
drug approval
europe
pregnancy
breast feeding
drug interactions
drugs, generic
drug therapy, combination
lymphoma, mantle-cell
antineoplastic agents
proteasome inhibitors
proteasome inhibitors
injections, intravenous
Bortezomib 3.5mg lyophilized powder for injection (product)
adult
drug evaluation, preclinical
antineoplastic agents
multiple myeloma
treatment outcome
bortezomib
drug evaluation
summary of product characteristics
package leaflet

---
https://www.ema.europa.eu/medicines/human/EPAR/Bortezomib-Hospira
2016
false
false
United Kingdom
English
French
syndication feed
Bortezomib
Bortezomib
drug approval
europe
pregnancy
breast feeding
drug interactions
drugs, generic
drug therapy, combination
lymphoma, mantle-cell
antineoplastic agents
proteasome inhibitors
proteasome inhibitors
injections, intravenous
Bortezomib 3.5mg lyophilized powder for injection (product)
adult
drug evaluation, preclinical
antineoplastic agents
multiple myeloma
treatment outcome
bortezomib
drug evaluation
summary of product characteristics
package leaflet

---
http://www.has-sante.fr/portail/jcms/c_2024414/fr/decision-n-2015-0065/dc/sem-du-25-mars-2015-du-college-de-la-haute-autorite-de-sante-adoptant-la-recommandation-relative-a-la-prise-en-charge-a-titre-derogatoire-du-bortezomib-velcade-1-et-3-5-mg-poudre-pour-solution-injectable-dans-le-cadre-d-une-recommandation-temporaire-d-utilisation
2015
false
true
false
false
France
French
amylose
guidelines for drug use
French pre-residency program examination
Bortezomib
insurance, health, reimbursement
Non-amyloid monoclonal immunoglobulin deposition disease
AL amyloidosis
adult
injections, intravenous
injections, subcutaneous
drug therapy, combination
continuity of patient care
treatment outcome
amyloidosis

---
https://pgtmsite.files.wordpress.com/2024/01/bortezomib_ad_rapppgtm_postcs-revnm-7-mai_20150512.pdf
2015
Canada
drug information
On Treatment
Analysis
Identifier
bortezomib
Multiple
Bortezomib
No Treatment for Diabetes
Therapy Object
Myeloma
GDC Treatment Frequency Terminology
During Treatment
Treatment
multiple myeloma
multiple myeloma
Treat
Analyzed
Treatment Study
Use
Description
NCI CTEP SDC Myeloma Sub-Category Terminology
Treatment Epoch
Multiple Myeloma
Biomaterial Treatment

---
https://pgtmsite.files.wordpress.com/2024/01/bortezomib_protocolechumrevmcr_20150511.pdf
2015
Canada
drug information
Bortezomib
bortezomib
Bortezomib

---
http://www.has-sante.fr/portail/jcms/c_1727466/fr/velcade-bortezomib-inhibiteur-de-proteasome
http://www.has-sante.fr/portail/jcms/c_1727466/fr/velcade
2014
false
false
false
France
French
English
guidelines for drug use
evaluation of the transparency committee
treatment outcome
bortezomib
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
multiple myeloma
injections, intravenous
adult
induction chemotherapy
hematopoietic stem cell transplantation
Bortezomib
Bortezomib

---
https://www.jle.com/fr/revues/medecine/hma/e-docs/00/04/8F/03/article.phtml
2013
Bortezomib
journal article
multiple myeloma
Myeloma
hematopoietic stem cells
cell proliferation
transplantation, autologous

---
http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/15858a-fra.php
2012
false
Canada
French
English
pharmacovigilance note
Bortezomib
Bortezomib
antineoplastic agents
antineoplastic agents
bortezomib
injections, spinal
injections, intravenous
multiple myeloma
cause of death

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00299
2011
false
false
false
Canada
Bortezomib
drug information
powders
injections

---
http://www.has-sante.fr/portail/jcms/c_921644/velcade-bortezomib-inhibiteur-du-proteasome-26s
2010
France
Bortezomib
evaluation of the transparency committee
proteasome inhibitors

---
https://pgtmsite.files.wordpress.com/2024/01/bortezomib_1ere_ligne_es_20100921.pdf
2010
false
false
false
Canada
French
scientific and technical information
multiple myeloma
Myeloma
intention
bortezomib
multiple myeloma
therapeutics
Bortezomib
treaties
international cooperation

---
http://www.has-sante.fr/portail/jcms/c_825465/caelyx-doxorubicine-liposomale-pegylee-anthracycline
http://www.has-sante.fr/portail/jcms/c_825463/synthese-d-avis-caelyx-ct-6273
http://www.has-sante.fr/portail/jcms/c_809258/caelyx-ct-6273
2009
false
France
French
Bortezomib
antineoplastic combined chemotherapy protocols
polyethylene glycols
doxorubicin
liposomal doxorubicin
doxorubicin hydrochloride
doxorubicin
antibiotics, antineoplastic
multiple myeloma
antineoplastic agents
liposomes
doxorubicin
guidelines for drug use
evaluation of the transparency committee

---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/719
2009
false
false
Canada
French
Bortezomib
melphalan
drug therapy, combination
multiple myeloma
prednisone
antineoplastic agents
protease inhibitors
antineoplastic agents, alkylating
antineoplastic combined chemotherapy protocols
disease progression
treatment outcome
survival analysis
antineoplastic combined chemotherapy protocols
critical appraisal or critical reading

---
http://www.msss.gouv.qc.ca/sujets/organisation/lutte-contre-le-cancer/documents/guides-cepo-pdf/CEPO-Bort%C3%A9zomib_et_MM_(2005-03).pdf
2005
false
false
Canada
French
Bortezomib
antineoplastic agents
proteasome inhibitors
multiple myeloma
treatment outcome
multiple myeloma
multiple myeloma
quebec
bibliography of medicine
drug therapy, combination
bortezomib
graph
guidelines for drug use

---
https://pgtmsite.files.wordpress.com/2024/01/bortezomib_myelomemultiple_pgtm_20050922.pdf
2005
Canada
drug information
bortezomib
Bortezomib
multiple myeloma
Multiple
NCI CTEP SDC Myeloma Sub-Category Terminology
multiple myeloma
Bortezomib
Myeloma
Multiple Myeloma

---
http://www.has-sante.fr/portail/display.jsp?id=c_245310
2004
false
France
French
Bortezomib
proteasome inhibitors
multiple myeloma
disease progression
treatment outcome
antineoplastic agents
bortezomib
guidelines for drug use

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.